Navigation Links
Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
Date:7/8/2009

r 31, 2008 previously filed with the SEC. Additional information regarding the interests of those persons may be obtained by reading the proxy statement relating to the proposed amendments.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with five regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force, which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement

Statements in this press release regarding the progress and timing of our product development programs and related trials; our future opportunities; our strategy, future operations, financial position, future revenues and projected costs; our management's prospects, plans and objectives; and any other statements about management's future expectations, beliefs, goals, plans or prospects constitute forward-looki
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
2. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
3. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
4. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... 11 EntreMed, Inc. (Nasdaq: ENMD ... in royalty revenue from sales of Thalomid® during ... of $3.3 million. In addition, the Company ... revenue for fiscal 2009. The difference in ... will be reflected in the fourth quarter financial ...
(Date:12/11/2009)... December 2009 -- Researchers have discovered a new explanation for ... more excess copies of a certain gene, the more serious ... and it is suspected that it is the amount of ... are being published in the American Journal of Human ... group of Guy Froyen connected to VIB, a life sciences ...
(Date:12/11/2009)... December 11 Algeta ASA (OSE: ... first clinical center in the,US, the Tulane ... patients,in the phase III clinical study of ... hormone-refractory) prostate cancer,(CRPC) that has metastasized to ... The ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) ...
(Date:12/11/2009)... Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" or the ... Warrander to the role of Senior Vice President, ... will be responsible for the execution of the ... Thompson, President and CEO of Oncolytics. "Having reached ... 3 trial examining REOLYSIN in combination with paclitaxel ...
Breaking Biology Technology:EntreMed Reports Receipt of Third Quarter Royalty Payment 2Amount of gene surplus determines severity of mental retardation in males 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3
... $8.1 Million Financing in ... Reverse Stock Split Planned for January ... ) today announced that the Company has:, - Signed an ... company based in Israel. The acquisition,is expected to close tomorrow. The ...
... Dec. 4 Immtech Pharmaceuticals,Inc. (AMEX: IMM ... an exclusive,license to BioAlliance Pharma SA (Euronext Paris ... pafuramidine maleate (pafuramidine), in,Europe for the treatment of ... treatment of Human African trypanosomiasis, also known as,African ...
... Healthcare,Technologies Ltd. (NASDAQ: HCTL ), announced today ... shareholders (approximately 90%),voted in favor of the NexGen ... were asked to approve the previously,announced Asset Purchase ... Gamida for Life B.V. and the transactions contemplated,thereby, ...
Other Biology Technology:Amarin Signs Agreement to Acquire Ester Neurosciences 2Amarin Signs Agreement to Acquire Ester Neurosciences 3Amarin Signs Agreement to Acquire Ester Neurosciences 4Amarin Signs Agreement to Acquire Ester Neurosciences 5Amarin Signs Agreement to Acquire Ester Neurosciences 6Amarin Signs Agreement to Acquire Ester Neurosciences 7Amarin Signs Agreement to Acquire Ester Neurosciences 8Amarin Signs Agreement to Acquire Ester Neurosciences 9Amarin Signs Agreement to Acquire Ester Neurosciences 10Amarin Signs Agreement to Acquire Ester Neurosciences 11Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 2Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 3Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 4Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction 2
(Date:12/15/2009)... San Diego, California, has been awarded an accreditation ... on results of a recent onsite inspection. ... this national recognition and congratulated for the "excellence ... GenWay Clinical Laboratory is one of nearly 7,000 ... Program, begun in the early 1960s, is recognized ...
(Date:12/15/2009)... researchers found the fossil remains of a whale, 4.5 million ... the first time, the results of the decay and fossilisation ... possibly a baleen whale from the Mysticeti group. , This ... of a whale from the Lower Pliocene (five million years ... the first time that the results of the processes of ...
(Date:12/15/2009)... standard laboratory model organism, but there are currently ... blood and blood-forming tissues in this species. ... laboratory resources from Cold Spring Harbor Laboratory Press ... features step-by-step protocols for the preparation, enumeration, and ... other hematopoietic tissues in the mouse. The ...
Breaking Biology News(10 mins):Story of 4.5 million-year-old whale unveiled in Huelva 2Story of 4.5 million-year-old whale unveiled in Huelva 3New source of classical techniques for blood-based studies in the laboratory mouse 2IPC The Hospitalist Company Inc to Report Second Quarter 2009 Results 52237 1IPC The Hospitalist Company Inc to Report Second Quarter 2009 Results 52237 2BioNeutrals Ygiene 28TM 29 Hospital Grade Achieves a 100 25 Total Kill 28Pass 29 Against the Life Threatening Clostridium Difficile 28C diff 29 Spor 13123 1BioNeutrals Ygiene 28TM 29 Hospital Grade Achieves a 100 25 Total Kill 28Pass 29 Against the Life Threatening Clostridium Difficile 28C diff 29 Spor 13123 2BioNeutrals Ygiene 28TM 29 Hospital Grade Achieves a 100 25 Total Kill 28Pass 29 Against the Life Threatening Clostridium Difficile 28C diff 29 Spor 13123 3My InnerView and UW Eau Claire Announce New Online Health Management Certificate Program for Senior Care Professionals 52230 1My InnerView and UW Eau Claire Announce New Online Health Management Certificate Program for Senior Care Professionals 52230 2My InnerView and UW Eau Claire Announce New Online Health Management Certificate Program for Senior Care Professionals 52230 3
... the Dana-Farber Cancer Institute (Dana-Farber), Burnham Institute for ... Control and Prevention (CDC) have reported the identification ... unprecedented range of influenza A viruses, including avian ... and some seasonal influenza viruses. These antibodies have ...
... Mass., Feb. 17 LocatePLUS Holdings Corporation ... provider of investigative, identity validation, and homeland ... 2009 election of an entirely independent Board ... Board through the consent of a majority ...
... came in,first place in the global SIMagine competition, ... the world,s largest event for mobile communication.,The awarded ... and,enables fast-lane service using fingerprint recognition and mobile ... a global competition focusing on new innovative solutions ...
Other Biology News:Scientists identify human monoclonal antibodies effective against bird, seasonal flu viruses 2Scientists identify human monoclonal antibodies effective against bird, seasonal flu viruses 3LocatePLUS Announces Election of Independent Board 2LocatePLUS Announces Election of Independent Board 3LocatePLUS Announces Election of Independent Board 4Mobile Communication Market Opens up for Biometrics - Precise Biometrics Awarded 1st Prize at GSMA World Mobile Congress 2
...
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
... mixed TAMRA isomers are predominantly used for ... preferred for labeling peptides and nucleotides because ... that is often required in the conjugation ... 6-TAMRA for labeling peptides and proteins. 6-TAMRA ...
Biology Products: